HRP20201107T8 - Heteroaril amidi kao inhibitori proteinske agregacije - Google Patents

Heteroaril amidi kao inhibitori proteinske agregacije

Info

Publication number: HRP20201107T8
Authority: HR; Croatia
Prior art keywords: inhibitors; protein aggregation; heteroaryl amides; heteroaryl; amides
Prior art date: 2014-01-29

Application number

HRP20201107TT

Other languages

English (en)

Inventor

Emily M. Stocking

Wolfgang Wrasidlo

Original Assignee

UCB Biopharma SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-29

Filing date

2020-07-14

Publication date

2020-12-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201107(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-07-14 Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL

2020-10-30 Publication of HRP20201107T1 publication Critical patent/HRP20201107T1/hr

2020-12-11 Publication of HRP20201107T8 publication Critical patent/HRP20201107T8/hr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HRP20201107TT 2014-01-29 2020-07-14 Heteroaril amidi kao inhibitori proteinske agregacije HRP20201107T8 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461933246P	2014-01-29	2014-01-29
US201462078895P	2014-11-12	2014-11-12
EP18156929.4A EP3348556B1 (en)	2014-01-29	2015-01-28	Heteroaryl amides as inhibitors of protein aggregation

Publications (2)

Publication Number	Publication Date
HRP20201107T1 HRP20201107T1 (hr)	2020-10-30
HRP20201107T8 true HRP20201107T8 (hr)	2020-12-11

Family

ID=52484559

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HRP20180813TT HRP20180813T1 (hr)	2014-01-29	2018-05-24	Heteroaril amidi kao inhibitori proteinske agregacije
HRP20201107TT HRP20201107T8 (hr)	2014-01-29	2020-07-14	Heteroaril amidi kao inhibitori proteinske agregacije

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HRP20180813TT HRP20180813T1 (hr)	2014-01-29	2018-05-24	Heteroaril amidi kao inhibitori proteinske agregacije

Country Status (37)

Country	Link
US (3)	US9738635B2 (hr)
EP (2)	EP3348556B1 (hr)
JP (2)	JP6619741B2 (hr)
KR (1)	KR102383038B1 (hr)
CN (2)	CN106132960B (hr)
AP (1)	AP2016009347A0 (hr)
AU (1)	AU2015211119B2 (hr)
BR (2)	BR112016017344B1 (hr)
CA (1)	CA2937967C (hr)
CL (1)	CL2016001918A1 (hr)
CR (1)	CR20160394A (hr)
CY (2)	CY1120348T1 (hr)
DK (2)	DK3099684T3 (hr)
EA (1)	EA032374B1 (hr)
EC (1)	ECSP16070327A (hr)
ES (2)	ES2808978T3 (hr)
HK (1)	HK1231470A1 (hr)
HR (2)	HRP20180813T1 (hr)
HU (2)	HUE050964T2 (hr)
IL (1)	IL246987B (hr)
LT (2)	LT3348556T (hr)
ME (1)	ME03800B (hr)
MX (1)	MX2016009896A (hr)
MY (1)	MY187450A (hr)
NZ (1)	NZ722487A (hr)
PE (1)	PE20161393A1 (hr)
PH (1)	PH12016501493B1 (hr)
PL (2)	PL3099684T3 (hr)
PT (2)	PT3348556T (hr)
RS (2)	RS60547B1 (hr)
SA (1)	SA516371579B1 (hr)
SG (1)	SG11201606108RA (hr)
SI (2)	SI3099684T1 (hr)
TR (1)	TR201809440T4 (hr)
UA (1)	UA118209C2 (hr)
WO (1)	WO2015116663A1 (hr)
ZA (1)	ZA201605246B (hr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3099684T3 (en)	2014-01-29	2018-07-16	Ucb Biopharma Sprl	HETEROARYLAMIDS AS INHIBITORS OF PROTEIN AGGREGATION
EP3328379B1 (en) *	2015-07-29	2021-07-28	UCB Biopharma SRL	Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) *	2016-11-25	2017-10-10	刘淑兰	一种治疗慢性盆腔炎的药物
EA201991753A1 (ru) *	2017-01-26	2020-01-14	Юсб Байофарма Спрл	Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
EA201991756A1 (ru) *	2017-01-26	2020-01-23	Юсб Байофарма Спрл	Бисгетероарильные производные в качестве модуляторов агрегации белков
WO2018138088A1 (en) *	2017-01-26	2018-08-02	Ucb Biopharma Sprl	Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
AU2018265584B2 (en) *	2017-05-12	2023-09-28	Ludwig-Maximilians-Universität München	Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
CA3108484A1 (en)	2017-08-04	2019-02-07	Anthony Stewart Campbell	Inhibitors of microbially induced amyloid
WO2019089640A1 (en) *	2017-10-31	2019-05-09	Loma Linda University	Methods for treating traumatic brain injury
CN112912376A (zh)	2018-08-20	2021-06-04	阿尔维纳斯运营股份有限公司	用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CN118488951A (zh)	2021-12-27	2024-08-13	上海京新生物医药有限公司	作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) *	2022-09-21	2022-11-02	Wista Lab Ltd	Tau aggregation inhibitors
WO2024094731A1 (en) *	2022-11-02	2024-05-10	Ac Immune Sa	Novel compounds for the diagnosis of tdp-43 proteinopathies
WO2024184179A1 (en)	2023-03-06	2024-09-12	UCB Biopharma SRL	Minzasolmin for use in the treatment of parkinson's disease
WO2024184180A1 (en)	2023-03-06	2024-09-12	UCB Biopharma SRL	Minzasolmin for use in the treatment of parkinson's disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1463997A (en) *	1995-12-22	1997-07-17	Acea Pharmaceuticals, Inc.	Subtype-selective nmda receptor ligands and the use thereof
EP1565446A1 (en) *	2002-11-28	2005-08-24	Schering Aktiengesellschaft	Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
CN101385722A (zh) *	2003-02-27	2009-03-18	乔安妮·麦克劳林	预防、治疗和诊断蛋白聚集疾病的方法
ES2284081T3 (es) *	2003-12-19	2007-11-01	Bristol-Myers Squibb Company	Heterociclos azabiciclicos como modulares de receptores canabinoides.
KR20070018824A (ko) *	2003-12-19	2007-02-14	브리스톨-마이어스 스큅 컴퍼니	카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
TW200530246A (en) *	2003-12-19	2005-09-16	Bristol Myers Squibb Co	Azabicyclic heterocycles as cannabinoid receptor modulators
JP4242911B2 (ja) *	2004-08-26	2009-03-25	ファイザー・インク	プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
EP1797084A1 (en) *	2004-09-20	2007-06-20	4Sc Ag	NOVEL HETEROCYCLIC NF-kB INHIBITORS
SE0403119D0 (sv) *	2004-12-21	2004-12-21	Astrazeneca Ab	Therapeutic agents
WO2007006546A1 (en) *	2005-07-11	2007-01-18	Devgen N.V.	Amide derivatives as kinase inhibitors
NZ588971A (en) *	2005-07-29	2012-06-29	4Sc Discovery Gmbh	Novel heterocyclic NF-kappaB inhibitors
BRPI0709595A2 (pt) *	2006-03-15	2011-07-19	4Sc Ag	inibidores de nf-kapab heterocìclicos
US8362066B2 (en) *	2006-11-17	2013-01-29	Treventis Corporation	Compounds and methods for treating protein folding disorders
EP2155226A4 (en) *	2007-06-14	2010-07-28	Univ California	COMPOUNDS FOR INHIBITING AGGREGATION OF PROTEINS AND METHODS OF MAKING AND USING SAME
US8598356B2 (en) *	2008-11-25	2013-12-03	Janssen Pharmaceutica Nv	Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) *	2009-06-11	2009-07-22	Univ Leuven Kath	Novel compounds for the treatment of neurodegenerative diseases
EP2491026A1 (en) *	2009-10-20	2012-08-29	Pfizer Inc.	Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
NZ600449A (en) *	2009-12-16	2014-10-31	Neuropore Therapies Inc	Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) *	2010-12-13	2011-01-26	Univ Leuven Kath	New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en)	2012-03-06	2013-09-12	Neuropore Therapies, Inc.	Methods and compounds to be used in the treatment of neurodegenerative diseases
EP2830608B8 (en)	2012-03-28	2020-01-15	UCB Biopharma SRL	Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
KR20150031481A (ko) *	2012-07-16	2015-03-24	뉴로포레 테라피스, 인코포레이티드	단백질 응집 저해제로서의 디- 및 트리-헤테로아릴 유도체
DK3099684T3 (en)	2014-01-29	2018-07-16	Ucb Biopharma Sprl	HETEROARYLAMIDS AS INHIBITORS OF PROTEIN AGGREGATION
EP3328379B1 (en)	2015-07-29	2021-07-28	UCB Biopharma SRL	Bis-heteroaryl derivatives as modulators of protein aggregation
WO2018138088A1 (en)	2017-01-26	2018-08-02	Ucb Biopharma Sprl	Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
EA201991756A1 (ru)	2017-01-26	2020-01-23	Юсб Байофарма Спрл	Бисгетероарильные производные в качестве модуляторов агрегации белков

2015
- 2015-01-28 DK DK15705417.2T patent/DK3099684T3/en active
- 2015-01-28 JP JP2016549488A patent/JP6619741B2/ja active Active
- 2015-01-28 RS RS20200827A patent/RS60547B1/sr unknown
- 2015-01-28 PT PT181569294T patent/PT3348556T/pt unknown
- 2015-01-28 HU HUE18156929A patent/HUE050964T2/hu unknown
- 2015-01-28 BR BR112016017344-9A patent/BR112016017344B1/pt active IP Right Grant
- 2015-01-28 EP EP18156929.4A patent/EP3348556B1/en active Active
- 2015-01-28 BR BR122018001892-5A patent/BR122018001892B1/pt active IP Right Grant
- 2015-01-28 EA EA201691529A patent/EA032374B1/ru unknown
- 2015-01-28 PL PL15705417T patent/PL3099684T3/pl unknown
- 2015-01-28 UA UAA201609003A patent/UA118209C2/uk unknown
- 2015-01-28 HU HUE15705417A patent/HUE040274T2/hu unknown
- 2015-01-28 DK DK18156929.4T patent/DK3348556T3/da active
- 2015-01-28 MX MX2016009896A patent/MX2016009896A/es active IP Right Grant
- 2015-01-28 MY MYPI2016001401A patent/MY187450A/en unknown
- 2015-01-28 LT LTEP18156929.4T patent/LT3348556T/lt unknown
- 2015-01-28 PT PT15705417T patent/PT3099684T/pt unknown
- 2015-01-28 EP EP15705417.2A patent/EP3099684B8/en active Active
- 2015-01-28 RS RS20180644A patent/RS57533B1/sr unknown
- 2015-01-28 AP AP2016009347A patent/AP2016009347A0/en unknown
- 2015-01-28 CA CA2937967A patent/CA2937967C/en active Active
- 2015-01-28 CN CN201580017216.1A patent/CN106132960B/zh active Active
- 2015-01-28 PL PL18156929T patent/PL3348556T3/pl unknown
- 2015-01-28 ES ES18156929T patent/ES2808978T3/es active Active
- 2015-01-28 CR CR20160394A patent/CR20160394A/es unknown
- 2015-01-28 NZ NZ722487A patent/NZ722487A/en unknown
- 2015-01-28 SG SG11201606108RA patent/SG11201606108RA/en unknown
- 2015-01-28 CN CN201911278647.XA patent/CN111039939B/zh active Active
- 2015-01-28 PE PE2016001285A patent/PE20161393A1/es unknown
- 2015-01-28 LT LTEP15705417.2T patent/LT3099684T/lt unknown
- 2015-01-28 KR KR1020167023810A patent/KR102383038B1/ko active IP Right Grant
- 2015-01-28 TR TR2018/09440T patent/TR201809440T4/tr unknown
- 2015-01-28 SI SI201530252T patent/SI3099684T1/en unknown
- 2015-01-28 ME MEP-2020-148A patent/ME03800B/me unknown
- 2015-01-28 ES ES15705417.2T patent/ES2675301T3/es active Active
- 2015-01-28 AU AU2015211119A patent/AU2015211119B2/en active Active
- 2015-01-28 WO PCT/US2015/013263 patent/WO2015116663A1/en active Application Filing
- 2015-01-28 SI SI201531297T patent/SI3348556T1/sl unknown
- 2015-12-29 US US14/983,243 patent/US9738635B2/en active Active
2016
- 2016-07-27 IL IL246987A patent/IL246987B/en unknown
- 2016-07-28 PH PH12016501493A patent/PH12016501493B1/en unknown
- 2016-07-28 CL CL2016001918A patent/CL2016001918A1/es unknown
- 2016-07-28 ZA ZA2016/05246A patent/ZA201605246B/en unknown
- 2016-07-28 SA SA516371579A patent/SA516371579B1/ar unknown
- 2016-08-29 EC ECIEPI201670327A patent/ECSP16070327A/es unknown
2017
- 2017-05-18 HK HK17105014.2A patent/HK1231470A1/zh unknown
- 2017-08-01 US US15/666,503 patent/US10358443B2/en active Active
2018
- 2018-05-24 HR HRP20180813TT patent/HRP20180813T1/hr unknown
- 2018-06-15 CY CY20181100630T patent/CY1120348T1/el unknown
2019
- 2019-06-04 JP JP2019104159A patent/JP6783900B2/ja active Active
- 2019-06-11 US US16/438,348 patent/US11078196B2/en active Active
2020
- 2020-07-14 HR HRP20201107TT patent/HRP20201107T8/hr unknown
- 2020-07-24 CY CY20201100682T patent/CY1123374T1/el unknown

Also Published As

Publication number	Publication date
EP3099684B1 (en)	2018-04-04
CA2937967C (en)	2022-07-26
RS60547B1 (sr)	2020-08-31
DK3099684T3 (en)	2018-07-16
JP6783900B2 (ja)	2020-11-11
BR112016017344B1 (pt)	2023-05-16
CY1120348T1 (el)	2019-07-10
NZ722487A (en)	2022-04-29
KR20160113287A (ko)	2016-09-28
PL3099684T3 (pl)	2018-09-28
AU2015211119A1 (en)	2016-08-11
HUE050964T2 (hu)	2021-01-28
ME03800B (me)	2021-04-20
PL3348556T3 (pl)	2020-11-02
KR102383038B1 (ko)	2022-04-05
HK1231470A1 (zh)	2017-12-22
US20190308965A1 (en)	2019-10-10
ES2808978T3 (es)	2021-03-02
WO2015116663A8 (en)	2016-09-15
CR20160394A (es)	2016-11-01
BR122018001892B1 (pt)	2023-05-02
LT3348556T (lt)	2020-08-10
CA2937967A1 (en)	2015-08-06
SG11201606108RA (en)	2016-08-30
US10358443B2 (en)	2019-07-23
PT3099684T (pt)	2018-10-22
UA118209C2 (uk)	2018-12-10
WO2015116663A1 (en)	2015-08-06
JP6619741B2 (ja)	2019-12-11
PT3348556T (pt)	2020-07-27
JP2019163321A (ja)	2019-09-26
TR201809440T4 (tr)	2018-07-23
HRP20201107T1 (hr)	2020-10-30
CN111039939A (zh)	2020-04-21
AU2015211119B2 (en)	2019-05-30
SI3348556T1 (sl)	2020-10-30
HUE040274T2 (hu)	2019-03-28
JP2017505779A (ja)	2017-02-23
AU2015211119A8 (en)	2016-12-15
US20180093979A1 (en)	2018-04-05
ZA201605246B (en)	2022-05-25
SA516371579B1 (ar)	2019-07-16
CN106132960A (zh)	2016-11-16
PH12016501493A1 (en)	2017-02-06
LT3099684T (lt)	2018-06-25
EP3348556A1 (en)	2018-07-18
EA032374B1 (ru)	2019-05-31
MX2016009896A (es)	2017-01-11
CY1123374T1 (el)	2021-12-31
CN106132960B (zh)	2019-12-17
EA201691529A1 (ru)	2017-01-30
BR112016017344A2 (pt)	2017-10-03
AP2016009347A0 (en)	2016-07-31
ES2675301T3 (es)	2018-07-10
PH12016501493B1 (en)	2017-02-06
IL246987B (en)	2021-12-01
US11078196B2 (en)	2021-08-03
ECSP16070327A (es)	2018-05-31
EP3099684A1 (en)	2016-12-07
MY187450A (en)	2021-09-22
ES2808978T8 (es)	2021-03-22
US9738635B2 (en)	2017-08-22
EP3099684B8 (en)	2018-07-04
CN111039939B (zh)	2023-09-19
PE20161393A1 (es)	2017-01-08
SI3099684T1 (en)	2018-08-31
US20160207912A1 (en)	2016-07-21
EP3348556B1 (en)	2020-04-29
DK3348556T3 (da)	2020-08-03
CL2016001918A1 (es)	2017-01-13
RS57533B1 (sr)	2018-10-31
HRP20180813T1 (hr)	2018-07-27
IL246987A0 (en)	2016-09-29

Publication	Publication Date	Title
HRP20201107T8 (hr)	2020-12-11	Heteroaril amidi kao inhibitori proteinske agregacije
ZA201702402B (en)	2020-07-29	Heteroaryl compounds as irak inhibitors and uses thereof
HK1245774A1 (zh)	2018-08-31	Copanlisib及其二鹽酸鹽的合成
HRP20190527T1 (hr)	2019-05-17	Sinteza kopanlisiba i njegove dihidrokloridne soli
IL251568A0 (en)	2017-06-29	Aminopyridine substances are effective as prenylation inhibitors in proteins
GB201415425D0 (en)	2014-10-15	Small molecule inhibitors of classiv bromodomain proteins